Lacrimal drug delivery device

US11207211B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11207211-B2
Application numberUS-201716302514-A
CountryUS
Kind codeB2
Filing dateMay 18, 2017
Priority dateMay 20, 2016
Publication dateDec 28, 2021
Grant dateDec 28, 2021

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A lacrimal drug delivery device includes a reservoir configured to hold a drug. The reservoir is moveable between a relaxed state and an expanded state. A connector is fluidly coupled to the reservoir and a lumen is formed in the connector wherein the drug is configured to flow from the reservoir to an delivery site through the lumen. A hydrogel is within the lumen and configured to absorb the drug from the reservoir and deliver the drug from the lumen at the delivery site. The hydrogel includes a first section which absorbs the drug at a first rate of absorption. A delivery guide is detachably coupled to the reservoir to deliver the reservoir into a lacrimal sac of a patient.

First claim

Opening claim text (preview).

We claim: 1. A lacrimal drug delivery device, comprising: a reservoir configured to hold a drug, the reservoir expandable between a relaxed state and an expanded state; a connector fluidly coupled to the reservoir, the connector including a first lumen formed in the connector configured such that drug flows from the reservoir to a delivery site through the lumen during use, and a second lumen formed in the connector and configured to run in parallel orientation to the first lumen and to removably receive a delivery guide within the second lumen, wherein the second lumen is in fluid communication with the reservoir; a hydrogel within the first lumen, the hydrogel being configured to absorb drug from the reservoir and to control the rate of flow of drug from the reservoir to the delivery site during use, the hydrogel including a first section which absorbs drug at a first rate of absorption; and a delivery guide detachably coupled to the reservoir to deliver the reservoir into a lacrimal sac of a patient during use. 2. The lacrimal drug delivery device of claim 1 , wherein the hydrogel includes a second section which absorbs the drug at a second rate of absorption different from the first rate of absorption. 3. The lacrimal drug delivery device of claim 2 , wherein the first section and the second section are comprised of the same chemical formulation. 4. The lacrimal drug delivery device of claim 2 , wherein the first section and the second section have different chemical formulations. 5. The lacrimal drug delivery device of claim 4 , wherein the first section is hydrophilic and the second section is hydrophobic. 6. The lacrimal drug delivery device of claim 5 , wherein the first lumen includes a proximal end and a distal end and the ratio of the first section to the second section is greater at the proximal end than at the distal end. 7. The lacrimal drug delivery device of claim 6 , wherein the first section extends from the proximal end to the distal end such that drug is transferred along the first lumen through the first section during use. 8. The lacrimal drug delivery device of claim 2 , wherein the first section has a first thickness and the second section has a second thickness less than the first thickness such that the first section absorbs drug faster than the second section during use. 9. The lacrimal drug delivery device of claim 8 , wherein the first lumen has a distal diameter adjacent the reservoir and a proximal diameter opposite the reservoir, wherein the proximal diameter is smaller than the distal diameter. 10. The lacrimal drug delivery device of claim 2 , wherein the first section has a first porosity and the second section has a second porosity different from the first porosity. 11. The lacrimal drug delivery device of claim 10 , wherein the first rate of absorption and the second rate of absorption are at least partially controlled by the porosity, wherein a larger porosity provides a faster rate of absorption. 12. The lacrimal drug delivery device of claim 11 , wherein the first section is adjacent the reservoir and the second section is opposite the first section, the first porosity larger than the second porosity. 13. The lacrimal drug delivery device of claim 1 , wherein the hydrogel is configured such that it is in a dry state prior to use and a wetted state during use, wherein drug is absorbed by the hydrogel from the reservoir after the device is implanted. 14. The lacrimal drug delivery device of claim 1 , wherein the delivery guide comprises a guide wire. 15. The lacrimal drug delivery device of claim 1 , wherein the delivery guide includes an opening therethrough configured to deliver drug through the opening to the reservoir to thereby transfer the reservoir from the relaxed state to the expanded state during use. 16. The lacrimal drug delivery device of claim 1 , further comprising a valve within the second lumen which seals the second lumen when the delivery device is removed during use. 17. The lacrimal drug delivery device of claim 1 , further comprising a filter coupled to the connector, the filter configured to seal the hydrogel within the first lumen while allowing drug to flow through the filter during use. 18. The lacrimal drug delivery device of claim 17 , wherein the filter is configured to prevent external substances from contaminating the hydrogel. 19. The lacrimal drug delivery device of claim 17 , wherein the filter is configured to at least partially control flow of drug during use. 20. The lacrimal drug delivery device of claim 1 , wherein the reservoir is elastic such that the reservoir exerts a compressive force on the drug when the reservoir is in the expanded state. 21. The lacrimal drug delivery device of claim 1 , wherein the device is configured such that the delivery site during use is at least one of a lacrimal punctum and nasolacrimal duct. 22. A lacrimal drug delivery device, comprising: a reservoir configured to hold a drug, the reservoir moveable between a relaxed state and an expanded state; a connector fluidly coupled to the reservoir, the connector including a first lumen, a second lumen configured to run in parallel orientation to the first lumen, a proximal end, and a distal end, the connector configured such that drug flows from the reservoir to a delivery site through the first lumen and a delivery guide is removably received within the second lumen during use; a hydrogel within the first lumen, the hydrogel configured to absorb drug from the reservoir and to control the rate of flow of drug from the reservoir to the delivery site during use; a delivery guide within the second lumen and configured to transfer the reservoir between the relaxed state to the expanded state, the delivery guide detachably coupled to the reservoir to position the reservoir in a lacrimal sac of a patient during use; and a valve within the second lumen, the valve configured to seal the second lumen when the delivery guide is removed and to allow the delivery guide to be reinserted to retransfer the reservoir between the relaxed state and the expanded state during use. 23. The lacrimal drug delivery device of claim 22 , wherein the delivery guide includes an opening therethrough configured to deliver drug through the opening and into the reservoir to thereby transfer the reservoir from the relaxed state to the expanded state during use. 24. The lacrimal drug delivery device of claim 22 , wherein the hydrogel includes a first section with a first rate of absorption and a second section with a second rate of absorption different than the first rate of absorption.

Assignees

Inventors

Classifications

  • Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00 · CPC title

  • Ocular inserts or implants · CPC title

  • A61F9/0008Primary

    Introducing ophthalmic products into the ocular cavity or retaining products therein (putting in contact lenses A61F9/0061; introducing or retaining media in cavities of the body in general A61M31/00) · CPC title

  • Ophthalmic agents · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11207211B2 cover?
A lacrimal drug delivery device includes a reservoir configured to hold a drug. The reservoir is moveable between a relaxed state and an expanded state. A connector is fluidly coupled to the reservoir and a lumen is formed in the connector wherein the drug is configured to flow from the reservoir to an delivery site through the lumen. A hydrogel is within the lumen and configured to absorb the …
Who is the assignee on this patent?
Univ Colorado Regents
What technology area does this patent fall under?
Primary CPC classification A61F9/0008. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).